Cargando…

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanakieva, Desislava, Pekar, Lukas, Evers, Andreas, Fleischer, Markus, Keller, Stephan, Mueller-Pompalla, Dirk, Toleikis, Lars, Kolmar, Harald, Zielonka, Stefan, Krah, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757479/
https://www.ncbi.nlm.nih.gov/pubmed/35014603
http://dx.doi.org/10.1080/19420862.2021.2018960
_version_ 1784632690356518912
author Yanakieva, Desislava
Pekar, Lukas
Evers, Andreas
Fleischer, Markus
Keller, Stephan
Mueller-Pompalla, Dirk
Toleikis, Lars
Kolmar, Harald
Zielonka, Stefan
Krah, Simon
author_facet Yanakieva, Desislava
Pekar, Lukas
Evers, Andreas
Fleischer, Markus
Keller, Stephan
Mueller-Pompalla, Dirk
Toleikis, Lars
Kolmar, Harald
Zielonka, Stefan
Krah, Simon
author_sort Yanakieva, Desislava
collection PubMed
description Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications.
format Online
Article
Text
id pubmed-8757479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-87574792022-01-14 Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities Yanakieva, Desislava Pekar, Lukas Evers, Andreas Fleischer, Markus Keller, Stephan Mueller-Pompalla, Dirk Toleikis, Lars Kolmar, Harald Zielonka, Stefan Krah, Simon MAbs Report Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications. Taylor & Francis 2022-01-11 /pmc/articles/PMC8757479/ /pubmed/35014603 http://dx.doi.org/10.1080/19420862.2021.2018960 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Yanakieva, Desislava
Pekar, Lukas
Evers, Andreas
Fleischer, Markus
Keller, Stephan
Mueller-Pompalla, Dirk
Toleikis, Lars
Kolmar, Harald
Zielonka, Stefan
Krah, Simon
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title_full Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title_fullStr Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title_full_unstemmed Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title_short Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
title_sort beyond bispecificity: controlled fab arm exchange for the generation of antibodies with multiple specificities
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757479/
https://www.ncbi.nlm.nih.gov/pubmed/35014603
http://dx.doi.org/10.1080/19420862.2021.2018960
work_keys_str_mv AT yanakievadesislava beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT pekarlukas beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT eversandreas beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT fleischermarkus beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT kellerstephan beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT muellerpompalladirk beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT toleikislars beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT kolmarharald beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT zielonkastefan beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities
AT krahsimon beyondbispecificitycontrolledfabarmexchangeforthegenerationofantibodieswithmultiplespecificities